A Review of Clonal Relationships in Myeloproliferative Neoplasms With Co-Mutations of JAK2, CALR or MPL and BCR::ABL1

IF 2.7 4区 医学 Q2 HEMATOLOGY Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-04-01 Epub Date: 2024-12-05 DOI:10.1016/j.clml.2024.11.007
Mohammadamin Noorafrooz , Sanaz Ghods , Robert Peter Gale , Ramin Noorafrooz
{"title":"A Review of Clonal Relationships in Myeloproliferative Neoplasms With Co-Mutations of JAK2, CALR or MPL and BCR::ABL1","authors":"Mohammadamin Noorafrooz ,&nbsp;Sanaz Ghods ,&nbsp;Robert Peter Gale ,&nbsp;Ramin Noorafrooz","doi":"10.1016/j.clml.2024.11.007","DOIUrl":null,"url":null,"abstract":"<div><div><em>BCR::ABL1-</em>negative myelo-proliferative neoplasms (MPNs) are characterized by mutations in <em>JAK2, CALR</em>, or <em>MPL</em>. Usually these mutations are co-exclusive of each other and of <em>BCR::ABL1</em>. We reviewed clonal interactions in 177 subjects with mutations in <em>JAK2, CALR</em>, or <em>MPL</em> and <em>BCR::ABL1</em> including <em>JAK2/BCR::ABL1</em> (<em>N</em> = 142), <em>CALR/BCR::ABL1</em> (<em>N</em> = 31), <em>MPL/BCR::ABL1</em> (<em>N</em> = 3). Co-mutations can arise in the same clone or in different sub-clones. In this review we used clonality data, mutation sequencing and therapy response evaluation to address this question. We found that in subjects with <em>JAK2/BCR::ABL1</em> co-mutations there is a complex, branched clonal evolution. In contrast, in subjects with <em>CALR/BCR::ABL1,</em> co-mutations are in different sub-clones. There are too few data in subjects with <em>MPL/BCR::ABL1</em> to critically analyze. However, indirect methods for assessing clonality limit our conclusions. Understanding clonal architecture of MPNs with co-mutations is needed to understand the underlying biology and give appropriate therapy.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 4","pages":"Pages 249-253"},"PeriodicalIF":2.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2152265024024182","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

BCR::ABL1-negative myelo-proliferative neoplasms (MPNs) are characterized by mutations in JAK2, CALR, or MPL. Usually these mutations are co-exclusive of each other and of BCR::ABL1. We reviewed clonal interactions in 177 subjects with mutations in JAK2, CALR, or MPL and BCR::ABL1 including JAK2/BCR::ABL1 (N = 142), CALR/BCR::ABL1 (N = 31), MPL/BCR::ABL1 (N = 3). Co-mutations can arise in the same clone or in different sub-clones. In this review we used clonality data, mutation sequencing and therapy response evaluation to address this question. We found that in subjects with JAK2/BCR::ABL1 co-mutations there is a complex, branched clonal evolution. In contrast, in subjects with CALR/BCR::ABL1, co-mutations are in different sub-clones. There are too few data in subjects with MPL/BCR::ABL1 to critically analyze. However, indirect methods for assessing clonality limit our conclusions. Understanding clonal architecture of MPNs with co-mutations is needed to understand the underlying biology and give appropriate therapy.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
JAK2、CALR或MPL与BCR::ABL1共突变骨髓增殖性肿瘤克隆关系的研究进展
BCR: abl1阴性的骨髓增生性肿瘤(mpn)以JAK2、CALR或MPL突变为特征。通常这些突变相互排斥,也排斥BCR::ABL1。我们回顾了177例JAK2、CALR或MPL和BCR::ABL1突变的克隆相互作用,包括JAK2/BCR::ABL1 (N = 142)、CALR/BCR::ABL1 (N = 31)、MPL/BCR::ABL1 (N = 3)。共突变可以发生在同一克隆或不同亚克隆中。在这篇综述中,我们使用克隆数据、突变测序和治疗反应评估来解决这个问题。我们发现在JAK2/BCR::ABL1共突变的受试者中存在复杂的分支克隆进化。相反,在CALR/BCR::ABL1的受试者中,共突变发生在不同的亚克隆中。MPL/BCR::ABL1患者的数据太少,无法进行批判性分析。然而,评估克隆性的间接方法限制了我们的结论。了解具有共突变的mpn的克隆结构是了解潜在生物学和给予适当治疗的必要条件。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.70
自引率
3.70%
发文量
1606
审稿时长
26 days
期刊介绍: Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
期刊最新文献
Editorial Board Table of Contents Prognostic Impact of the Level of Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation on Pediatric Patients With Acute Lymphoblastic Leukemia: A 10-Year Single-Center Study Causes of Death Among Waldenström Macroglobulinemia Patients: A Population-Based Study What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1